Tenarine Tablets (Terbinafine Hydrochloride)
Terbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Hwail Pharmaceutical Co., Ltd.
MFDS item code 201908005 · Approved 2019.11.20
This product's status changed to Expired on 2024.11.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of onychomycosis, cutaneous fungal infections (tinea pedis, tinea corporis, etc.), and tinea capitis
This medicine is used for the treatment of tinea pedis, tinea corporis, tinea cruris, and onychomycosis caused by dermatophytes in adults. Additionally, it is effective for the treatment of tinea capitis in pediatric patients. In other words, it is used to improve fungal infections occurring on the skin and nails.
Administer 125 mg of terbinafine hydrochloride per dose twice daily, or 250 mg per dose once daily. The duration of administration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type) : 2~6 weeks Tinea corporis : 2∼4 weeks Tinea cruris : 2~4 weeks 2) Onychomycosis Administer for 6 weeks~3 months in most cases. For infections of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. A treatment duration of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment duration may be longer in patients with slow nail growth. Reduce the daily dose by 1/2 in patients with a creatinine clearance of less than 50 mL per minute.
Administer to children aged 2 years and older. Administration is not recommended for children under 2 years of age because there is no experience with use in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of the infection, treatment should be given regularly for the prescribed duration. Body weight under 20 kg (under 5 years): 62.5 mg per dose, once daily. Since experience with use is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): 125 mg per dose, once daily. Body weight over 40 kg (over 12 years): 250 mg per dose, once daily.
This medication is not recommended for patients with chronic liver disease or active liver disease. Liver function tests must be performed before treatment initiation, and liver function should be monitored regularly during treatment. If symptoms of liver dysfunction appear, discontinue the medication immediately and consult a physician. This medication should not be administered to patients with blood disorders, severe renal failure, nursing mothers, or children under 2 years old. Since it contains lactose, patients who are lactose intolerant should avoid taking it. It should be used with caution in patients with reduced kidney function, the elderly, and children weighing less than 20 kg. If serious skin reactions occur during the medication, discontinue it immediately and consult healthcare personnel. This medication may cause various side effects such as liver damage, blood dyscrasias, skin rashes, myalgia, gastrointestinal symptoms, and neurological symptoms, so careful monitoring is necessary. Caution is needed when driving or operating machinery if symptoms such as dizziness occur. There may be interactions with other medications, so inform healthcare personnel about any concomitant medications. For women who are pregnant or may become pregnant, the administration of this medication should be determined with caution, and breastfeeding should be discontinued if nursing. In cases of overdose, symptoms such as headache, nausea, and dizziness may occur, and immediate medical attention should be sought. Keep this medication out of reach of children and store it in a cool, dry place away from direct sunlight.
Liver and gallbladder insufficiency, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, fatigue, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, subcutaneous hemorrhage, leukopenia, anemia, rash, itching, photosensitivity reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, blistering dermatitis, psoriasis-like rash, exacerbation of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, dyspnea, chest tightness, urticaria, erythema, facial swelling, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, mild abdominal pain, diarrhea, gastric discomfort, thirst, vomiting, glossitis, depression, anxiety, headache, dysgeusia, dizziness, drowsiness, sensory disturbances, sensory loss, decreased attention, insomnia, elevated BUN, polyuria, visual impairment, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol, elevated triglyceride levels, fatigue, tongue discoloration, palpitations, edema, menstrual abnormalities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, diminished vision, hearing loss, auditory impairment, vasculitis, permanent anosmia, hyposmia, drug rash accompanied by eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased serum creatine phosphokinase.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from exposure to air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. This will help preserve the drug's efficacy for a longer period.
White round tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Terbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Hwail Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
GP Therapeutics Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Hutex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Anguk Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Medica Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Gyeongnam Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Daehwa Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.